ESSA Pharma Inc. faces securities fraud lawsuit from investors – ABC4 Utah
The Securities and Exchange Commission (SEC) has initiated an investigation into a company regarding potential violations. Investors who bought the company’s securities between December 12, 2023, and October 31, 2024, are being scrutinized as part of this inquiry.
The SEC is specifically examining the period from December 12, 2023, to October 31, 2024, concerning the company’s securities transactions. Investors who participated in buying or selling the securities during this timeframe are urged to pay close attention to the developments of this investigation.
The investigation by the SEC into the company’s securities spans from December 12, 2023, to October 31, 2024. Investors who engaged in transactions involving the company’s securities within this time frame should be aware of the ongoing inquiry and be prepared for potential outcomes.
Investors who acquired the company’s securities between December 12, 2023, and October 31, 2024, are now under the SEC’s scrutiny as part of an investigation into potential violations. The period in question covers a significant timeframe in which securities transactions took place, warranting a thorough examination by the regulatory body.
The SEC has launched a detailed investigation into a company’s securities activities, focusing on transactions conducted between December 12, 2023, and October 31, 2024. Investors who were involved in buying or selling the company’s securities during this specific timeframe are now being closely monitored as part of the inquiry.
